Jessica Lee, MD
Vascular Neurology · Lexington, KYNPI 1780650614
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $669 of the $918 with a category attached, or 72.8%. 5 manufacturers reported payments, led by Janssen Research & Development, LLC at 58.7% of the total. Reporting peaked in 2023 at $733 and has fallen 78.0% since, to $161 in 2024.
Across 24 payments — averaging $38.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$539
- Calliditas Therapeutics US Inc.$162
- GSK$125
- Supernus Pharmaceuticals, Inc.$70
- Genentech, Inc.$22
Across 15 payments — averaging $2515.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$36K
- Genentech, Inc.$2K
What the payments were for
- Travel & lodging$24927%
- Food & beverage$66973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 6 | $539 |
| Calliditas Therapeutics US Inc. | 10 | $162 |
| GSK | 6 | $125 |
| Supernus Pharmaceuticals, Inc. | 1 | $70 |
| Genentech, Inc. | 1 | $22 |
How this compares
Too few vascular neurology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 23 | $261 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Lexington
- Larry GoldsteinLexington$29K
- Mais Al-KawazLexington$4K
- Suhas GangadharaLexington$3K
- Homa SadeghianLexington$2K
- Richard MurphyLexington$108
- Kevin O'ConnorLexington$14
- Wei LiuLouisville$7K
- Tanya WarwickAshland$1K
- Tamika BurrusLouisville$267
- Roberto Chulluncuy RivasLouisville$55
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.